Get our free email newsletter

FDA Warns Medical Diagnostic Company of Violations

The U.S. Food and Drug Administration (FDA) has put a medical device manufacturer on notice for its failure to obtain proper approval for several versions of the company’s blood testing systems.

According to a warning letter sent by the FDA in October, the company, Magellan Diagnostics marketed “significantly modified” versions of two of its blood testing systems without the FDA’s required clearance or approval. The company also reportedly failed to submit to the FDA medical device reports after it became aware of customer complaints involving discrepancies in reported blood lead test results.

The warning letter stems from an investigation of Magellan’s facilities conducted by the FDA earlier this year in response to those consumer complaints. The FDA’s investigators reportedly observed evidence of the cited violations during their visit.

- Partner Content -

Three Vibration/Balancing Solutions for the Aviation Industry

This paper provides a quick overview of aerospace engine testing solutions for engine vibration/balancing as well as signal conditioning technology from MTI instruments.

The company has until November 10th to notify the FDA of the specific steps it has taken to address the identified violations and to prevent them from reoccurring. Should the company fail to respond, it may be subject to additional action, including product seizures, injunctions and civil monetary penalties.

Read a copy of the FDA’s warning letter to Magellan Diagnostics.

Related Articles

Digital Sponsors

Become a Sponsor

Discover new products, review technical whitepapers, read the latest compliance news, and check out trending engineering news.

Get our email updates

What's New

- From Our Sponsors -

Sign up for the In Compliance Email Newsletter

Discover new products, review technical whitepapers, read the latest compliance news, and trending engineering news.